Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment
Glioblastoma (GBM) is the most common aggressive primary brain tumor in adults, with a short survival time even after aggressive therapy. Non-invasive surrogate biomarkers of therapy response may be relevant for improving patient survival. Previous work produced such biomarkers in preclinical GBM us...
Main Authors: | Nuria Arias-Ramos, Laura Ferrer-Font, Silvia Lope-Piedrafita, Victor Mocioiu, Margarida Julià-Sapé, Martí Pumarola, Carles Arús, Ana Paula Candiota |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-05-01
|
Series: | Metabolites |
Subjects: | |
Online Access: | http://www.mdpi.com/2218-1989/7/2/20 |
Similar Items
-
Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches
by: Shuang Wu, et al.
Published: (2020-11-01) -
Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses
by: Pilar Calero-Pérez, et al.
Published: (2021-05-01) -
Efeito de nanoemulsão contendo oleato de paclitaxel em glioblastoma murino: estudos in vivo e in vitro
by: Marina Cecília Spatti
Published: (2016) -
Efeito de nanoemulsão contendo oleato de paclitaxel em glioblastoma murino: estudos in vivo e in vitro
by: Spatti, Marina Cecília
Published: (2016) -
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
by: Xueyuan Sun, et al.
Published: (2021-05-01)